West Hills Hospital
February 10, 2021

Antibody Treatment for COVID-19 administered at West Hills Hospital.

West Hills Hospital is currently offering monoclonal antibody treatment to select patients who meet criteria. These treatments have been shown to decrease hospitalization rates in people at highest risk for severe disease from COVID-19. The therapy is a one-time intravenous infusion within the first 10 days after diagnosis, and is being offered through our emergency department. The medication supply is limited and based on availability and examination by a physician with privileges at the hospital or by an emergency room physician. Eligible patients must have a confirmed diagnosis of COVID-19 infection and be 65 and over, or 55 and over and have one of the following associated conditions:

  • Obesity
  • Chronic kidney disease/li>
  • COPD
  • Asthma
  • Diabetes
  • Immunosuppressive disease
  • Heart disease
  • Treatment is not authorized for use for patients who
  • Are hospitalized due to COVID-19
  • Require oxygen therapy due to COVID-19
  • Require oxygen due to another underlying medical condition

“We are honored to provide this latest treatment option to our community,” says Donald David, MD, Chief Medical Officer West Hills Hospital & Medical Center. “We are hopeful this therapy will save lives and reduce hospital admissions.”

In November, the U.S. Food & Drug Administration (FDA) granted Emergency Authorized Use (EUA) of two monoclonal antibody therapeutics to treat mild to moderate COVID 19 non hospitalized patients who are at high risk to develop severe COVID-19. Bamlanivimab from Eli Lilly and Company was authorized for emergency use on November 9, and Regeneron’s therapeutic was authorized on November 21.